Historical Valuation
BioLine RX Ltd (BLRX) is now in the Fair zone, suggesting that its current forward PS ratio of 5.02 is considered Fairly compared with the five-year average of -1.59. The fair price of BioLine RX Ltd (BLRX) is between 2.68 to 4.24 according to relative valuation methord.
Relative Value
Fair Zone
2.68-4.24
Current Price：2.98
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
BioLine RX Ltd (BLRX) has a current Price-to-Book (P/B) ratio of 374.28. Compared to its 3-year average P/B ratio of 133.37 , the current P/B ratio is approximately 180.64% higher. Relative to its 5-year average P/B ratio of 81.96, the current P/B ratio is about 356.64% higher. BioLine RX Ltd (BLRX) has a Forward Free Cash Flow (FCF) yield of approximately -109.73%. Compared to its 3-year average FCF yield of -97.33%, the current FCF yield is approximately 12.74% lower. Relative to its 5-year average FCF yield of -71.05% , the current FCF yield is about 54.45% lower.
P/B
Median3y
133.37
Median5y
81.96
FCF Yield
Median3y
-97.33
Median5y
-71.05
Competitors Valuation Multiple
AI Analysis for BLRX
The average P/S ratio for BLRX competitors is 12.74, providing a benchmark for relative valuation. BioLine RX Ltd Corp (BLRX.O) exhibits a P/S ratio of 5.02, which is -60.61% above the industry average. Given its robust revenue growth of -91.36%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for BLRX
1Y
3Y
5Y
Market capitalization of BLRX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of BLRX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is BLRX currently overvalued or undervalued?
BioLine RX Ltd (BLRX) is now in the Fair zone, suggesting that its current forward PS ratio of 5.02 is considered Fairly compared with the five-year average of -1.59. The fair price of BioLine RX Ltd (BLRX) is between 2.68 to 4.24 according to relative valuation methord.
What is BioLine RX Ltd (BLRX) fair value?
BLRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of BioLine RX Ltd (BLRX) is between 2.68 to 4.24 according to relative valuation methord.
How does BLRX's valuation metrics compare to the industry average?
The average P/S ratio for BLRX's competitors is 12.74, providing a benchmark for relative valuation. BioLine RX Ltd Corp (BLRX) exhibits a P/S ratio of 5.02, which is -60.61% above the industry average. Given its robust revenue growth of -91.36%, this premium appears unsustainable.
What is the current P/B ratio for BioLine RX Ltd (BLRX) as of Jan 09 2026?
As of Jan 09 2026, BioLine RX Ltd (BLRX) has a P/B ratio of 374.28. This indicates that the market values BLRX at 374.28 times its book value.
What is the current FCF Yield for BioLine RX Ltd (BLRX) as of Jan 09 2026?
As of Jan 09 2026, BioLine RX Ltd (BLRX) has a FCF Yield of -109.73%. This means that for every dollar of BioLine RX Ltd’s market capitalization, the company generates -109.73 cents in free cash flow.
What is the current Forward P/E ratio for BioLine RX Ltd (BLRX) as of Jan 09 2026?
As of Jan 09 2026, BioLine RX Ltd (BLRX) has a Forward P/E ratio of -1.35. This means the market is willing to pay $-1.35 for every dollar of BioLine RX Ltd’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for BioLine RX Ltd (BLRX) as of Jan 09 2026?
As of Jan 09 2026, BioLine RX Ltd (BLRX) has a Forward P/S ratio of 5.02. This means the market is valuing BLRX at $5.02 for every dollar of expected revenue over the next 12 months.